AYTU BIOPHARMA, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
AYTU BIOPHARMA, INC (AYTU) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 2.79 thousand shares for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-09-22
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 1.41K shares, a 74.07% decline year-over-year.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was 5.44K shares.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 3.76K shares, a 1.05% decline year-over-year.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2026 was 2.79K shares, a 83.90% decline from fiscal 2025.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 17.34K shares, a 4.41% increase from fiscal 2024.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 16.61K shares, a 9556.98% increase from fiscal 2023.
- AYTU BIOPHARMA, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 172.00 shares, a 98.90% decline from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 1.41K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | 1.41K shares derived: sum of 2 quarters · filed 2026-09-22 | 2.79K shares 10-K · filed 2026-09-22 | ||
| 2026-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | 1.38K shares 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 1.38K shares 10-Q · filed 2026-02-03 | ||||
| 2025-06-30 | 5.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | 9.20K shares derived: sum of 2 quarters · filed 2025-09-23 | 12.24K shares derived: sum of 3 quarters · filed 2025-09-23 | 17.34K shares 10-K · filed 2025-09-23 | |
| 2025-03-31 | 3.76K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14 | 6.81K shares derived: sum of 2 quarters · filed 2025-05-14 | 11.91K shares 10-Q · filed 2025-05-14 | 9.66K shares derived: sum of 4 quarters · filed 2025-05-14 | |
| 2024-12-31 | 3.05K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | 8.15K shares 10-Q · filed 2025-02-12 | 5.90K shares derived: sum of 3 quarters · filed 2025-02-12 | 9.70K shares derived: sum of 4 quarters · filed 2025-02-12 | |
| 2024-09-30 | 5.10K shares 10-Q · filed 2024-11-13 | 2.85K shares derived: sum of 2 quarters · filed 2024-11-13 | 6.65K shares derived: sum of 3 quarters · filed 2024-11-13 | 19.66K shares derived: sum of 4 quarters · filed 2024-11-13 | |
| 2024-06-30 | -2.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | 1.55K shares derived: sum of 2 quarters · filed 2024-09-26 | 14.56K shares derived: sum of 3 quarters · filed 2024-09-26 | 16.61K shares 10-K · filed 2024-09-26 | |
| 2024-03-31 | 3.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | 16.81K shares derived: sum of 2 quarters · filed 2024-05-15 | 18.86K shares 10-Q · filed 2024-05-15 | 18.88K shares derived: sum of 4 quarters · filed 2024-05-15 | |
| 2023-12-31 | 13.02K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14 | 15.06K shares 10-Q · filed 2024-02-14 | 15.08K shares derived: sum of 3 quarters · filed 2024-02-14 | 15.08K shares derived: sum of 4 quarters · filed 2024-02-14 | |
| 2023-09-30 | 2.04K shares 10-Q · filed 2023-11-14 | 2.06K shares derived: sum of 2 quarters · filed 2023-11-14 | 2.07K shares derived: sum of 3 quarters · filed 2023-11-14 | 2.14K shares derived: sum of 4 quarters · filed 2023-11-14 | |
| 2023-06-30 | 20.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | 22.00 shares derived: sum of 2 quarters · filed 2023-10-12 | 98.00 shares derived: sum of 3 quarters · filed 2023-10-12 | 172.00 shares 10-K · filed 2023-10-12 | |
| 2023-03-31 | 2.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | 78.00 shares derived: sum of 2 quarters · filed 2023-05-11 | 152.00 shares 10-Q · filed 2023-05-11 | 589.00 shares derived: sum of 4 quarters · filed 2023-05-11 | |
| 2022-12-31 | 76.00 shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21 | 150.00 shares 10-Q · filed 2023-02-21 | 587.00 shares derived: sum of 3 quarters · filed 2023-02-21 | 6.36K shares derived: sum of 4 quarters · filed 2023-02-21 | |
| 2022-09-30 | 74.00 shares 10-Q/A · filed 2023-02-21 | 1.60K shares 10-Q · filed 2022-11-14 | 511.00 shares derived: sum of 2 quarters · filed 2023-02-21 | 6.29K shares derived: sum of 3 quarters · filed 2023-02-21 | 9.57K shares derived: sum of 4 quarters · filed 2023-02-21 |
| 2022-06-30 | 437.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | 6.21K shares derived: sum of 2 quarters · filed 2022-09-27 | 9.49K shares derived: sum of 3 quarters · filed 2022-09-27 | 15.57K shares 10-K · filed 2022-09-27 | |
| 2022-03-31 | 5.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | 9.05K shares derived: sum of 2 quarters · filed 2022-05-16 | 15.13K shares 10-Q · filed 2022-05-16 | ||
| 2021-12-31 | 3.28K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | 9.36K shares 10-Q · filed 2022-02-14 | |||
| 2021-09-30 | 6.08K shares 10-Q · filed 2021-11-15 | ||||
| 2021-03-31 | 7.55K shares 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | 3.19K shares 10-Q · filed 2021-02-11 | ||||
| 2017-03-31 | 8.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-11 | 23.90K shares derived: sum of 2 quarters · filed 2017-05-11 | 25.98K shares 10-Q · filed 2017-05-11 | ||
| 2016-12-31 | 15.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | 17.65K shares 10-Q · filed 2017-02-09 | |||
| 2016-09-30 | 2.08K shares 10-Q · filed 2016-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |